UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 18, 2009
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
TRANSACTION IN OWN SHARES
NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME
On 7 August 2009 Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission's regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to
DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.
Since the announcement as of 7 August 2009, the following transactions have been
made under the programme:
NUMBER OF AVERAGE TRANSACTION
SHARES PURCHASE PRICE VALUE, DKK
ACCUMULATED, LAST
ANNOUNCEMENT 0 0
10 August 2009 75,000 305.7500 22,931,250
11 August 2009 75,000 305.4400 22,908,000
12 August 2009 75,000 313.5000 23,512,500
13 August 2009 75,000 317.1900 23,789,250
14 August 2009 75,000 318.0500 23,853,750
ACCUMULATED UNDER THE
PROGRAMME 375,000 116,994,750
Transactions related to Novo Nordisk's incentive programmes have resulted in a
net sale by Novo Nordisk of 71,933 B shares in the period from 10 August 2009 to
14 August 2009. The shares in these transactions were not part of the Safe
Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 25,255,458
treasury shares, corresponding to 4.1% of the share capital. The total amount of
shares in the company is 620,000,000 including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81
countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.
Further information:
Media: Investors:
Outside North America: Outside North America:
Rachel Curtis Gravesen Mads Veggerby Lausten
Tel: (+45) 4442 7603 Tel: (+45) 4443 7919
rcgv@novonordisk.com mlau@novonordisk.com
Kasper Roseeuw Poulsen
Tel: 4442 4471
krop@novonordisk.com
In North America: In North America:
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com hrmm@novonordisk.com
Company Announcement no 50 / 2009
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: August 18, 2009 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer